<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00247702</url>
  </required_header>
  <id_info>
    <org_study_id>940609</org_study_id>
    <nct_id>NCT00247702</nct_id>
  </id_info>
  <brief_title>The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR</brief_title>
  <official_title>Study of the Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      Oral warfarin anticogulation for the prevention and treatment of patients with venous&#xD;
      thromboembolism is one of the most used therapies in clinical practice. Patients require&#xD;
      different dosage to achieve the target therapeutic anticoagulation. Optimal dosage and&#xD;
      bleeding complication are two most clinical concerns. Besides of multiple individual factors&#xD;
      (e.g. age, dietary intake, vitamin supplement, drug compliance etc.), some genetic factors&#xD;
      may determine the drug requirement and safety.&#xD;
&#xD;
      The cytochrome P450 CYP2C9 is a liver enzyme required for the oxidative metabolism of&#xD;
      warfarin. The vitamin K epoxide redutase (VKOR) is a liver enzyme associated with the reuse&#xD;
      of the oxidative hydroquinone form of vitamin K. The VKOR enzyme is the target of warfarin.&#xD;
      Recent studies revealed both genes may determine the pharmacodynamic of warfarin&#xD;
      anticogualation. To date, there are more than thirteen identified polymorphism at CYP2C9&#xD;
      gene. Majority of those variant polymorphisms may decrease the warfarin requirement. The VKOR&#xD;
      complex subunit 1 (VKORC1) is a newly identified gene. Some polymorphisms also were reported.&#xD;
&#xD;
      As we know, the Chinese patients need a lower dosage of warfarin in comparison with the&#xD;
      Caucasian patients. We are interested in finding the genetic causes of Taiwneses Chinese&#xD;
      patients. In our study we will first identify the polymorphism patterns of these two genes in&#xD;
      normal population. Then, we will try to find the association between these polymorphism and&#xD;
      patient warfarin requirement. Our pharmacogenetics study will be valuable for prevention of&#xD;
      bleeding complication of warfarin treatment in Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <completion_date>June 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>120</enrollment>
  <condition>Deep Venous Thromboembolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Use warfarin therapy for at least two months before study&#xD;
&#xD;
          -  Stable INR value during recent three months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  higher age(&gt;80 y/o)&#xD;
&#xD;
          -  liver and renal dysfunction&#xD;
&#xD;
          -  alcohol abuse&#xD;
&#xD;
          -  BMI&lt;18kg/m2&#xD;
&#xD;
          -  coadministered medicine that can affect pharmacokinetics or pharmacodynamics of&#xD;
             warfarin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tasy Wei, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan Univerisity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tsay Wei, Doctor</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>5040</phone_ext>
    <email>woei@ha.mc.ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsay Wei, Doctor</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>5040</phone_ext>
      <email>woei@ha.mc.ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <study_first_submitted>November 1, 2005</study_first_submitted>
  <study_first_submitted_qc>November 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2005</study_first_posted>
  <last_update_submitted>November 1, 2005</last_update_submitted>
  <last_update_submitted_qc>November 1, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2005</last_update_posted>
  <keyword>CYP2C9</keyword>
  <keyword>VKORC1</keyword>
  <keyword>polymorphism</keyword>
  <keyword>warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

